Phaseline

Companies › Hexin (Suzhou) Pharmaceutical Technology

Hexin (Suzhou) Pharmaceutical Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
68Ga-HX01 Injection Solution
Gallium-68 labeled PET imaging agent
–Phase 2Soft Tissue SarcomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0792083568Ga-HX01 Injection SolutionPhase 2Soft Tissue SarcomaOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.